Research Suggests GLP-1 Drugs May Slow Cancer Spread
Recent research indicates that glucagon-like peptide-1 (GLP-1) weight-loss medications may slow the progression of certain cancers. This study will be presented at the upcoming ASCO Annual Meeting in 2026 in Chicago.
Study and Findings
Conducted by the Cleveland Clinic, the study revealed that GLP-1 medications might reduce the spread of obesity-related cancers. These cancers include lung, breast, colorectal, and liver cancers.
The research involved 12,112 patients diagnosed with various obesity-related cancers (stages 1 to 3). The cancers included:
- Breast adenocarcinoma
- Prostate adenocarcinoma
- Non-small cell lung cancer (NSCLC)
- Colorectal adenocarcinoma
- Hepatocellular carcinoma
- Renal cell carcinoma
- Pancreatic adenocarcinoma
Comparative Results
Half of the participants began using a GLP-1 medication (such as semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide, or pramlintide) after their cancer diagnosis. The other half took DPP-4 inhibitors, another class of diabetes drugs.
When compared to those taking DPP-4 inhibitors, GLP-1 users experienced significantly lower rates of progression to stage 4 disease in four cancer types. Non-small cell lung cancer showed a 50% risk reduction, breast cancer 43%, colorectal cancer 31%, and liver cancer 38%.
“Our study found that use of GLP-1 drugs was associated with a meaningful reduction in cancer progression across four solid tumor types,” stated Dr. Mark David Orland of the Taussig Cancer Institute at Cleveland Clinic.
Potential and Limitations
For prostate, pancreatic, and kidney cancers, patients taking GLP-1s showed lower spread rates, though not statistically significant. The study also linked tumors with higher levels of GLP-1 receptors to improved survival outcomes.
The research indicated that patients with more GLP-1 receptors in their tumors had about a one-third lower risk of death during the study period.
Both GLP-1 and gliptin user groups reported similar adverse side effects. The findings raise the possibility that GLP-1 pathways may impact how certain cancers grow. However, more research is necessary to understand these mechanisms fully.
Despite its promising results, this study is retrospective and observational, which limits its ability to establish that GLP-1 drugs directly prevent cancer progression. Other factors like health conditions, weight loss, and metabolic changes could have affected the outcomes. More extensive randomized clinical trials are needed to confirm these preliminary results and explore how GLP-1s may affect cancer spread specifically.